60 related articles for article (PubMed ID: 22512262)
1. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.
Yuan X; Ruan W; Bobrow B; Carmeliet P; Eltzschig HK
Nat Rev Drug Discov; 2024 Mar; 23(3):175-200. PubMed ID: 38123660
[TBL] [Abstract][Full Text] [Related]
2. HIF repressors under chronic hypoxia.
Luo W; Wang Y
Aging (Albany NY); 2016 Mar; 8(3):418-9. PubMed ID: 26954058
[No Abstract] [Full Text] [Related]
3. Development of HIF-1 inhibitors for cancer therapy.
Onnis B; Rapisarda A; Melillo G
J Cell Mol Med; 2009 Sep; 13(9A):2780-6. PubMed ID: 19674190
[TBL] [Abstract][Full Text] [Related]
4. [The development of innovative therapeutic drugs targeting hypoxia responses].
Yoshikawa K; Hagimoto H; Nakamura E
Nihon Yakurigaku Zasshi; 2024; 159(3):160-164. PubMed ID: 38692880
[TBL] [Abstract][Full Text] [Related]
5. Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition.
Garcia MR; Andrade PB; Lefranc F; Gomes NGM
Mar Drugs; 2024 Mar; 22(4):. PubMed ID: 38667760
[TBL] [Abstract][Full Text] [Related]
6. Efficient targeting of HIF-1α mediated by YC-1 and PX-12 encapsulated niosomes: potential application in colon cancer therapy.
Bakand A; Moghaddam SV; Naseroleslami M; André H; Mousavi-Niri N; Alizadeh E
J Biol Eng; 2023 Sep; 17(1):58. PubMed ID: 37749603
[TBL] [Abstract][Full Text] [Related]
7. The Hypoxia-Long Noncoding RNA Interaction in Solid Cancers.
Son SW; Yun BD; Song MG; Lee JK; Choi SY; Kuh HJ; Park JK
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298879
[TBL] [Abstract][Full Text] [Related]
8. The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective.
Mammadzada P; Corredoira PM; André H
Cell Mol Life Sci; 2020 Mar; 77(5):819-833. PubMed ID: 31893312
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.
Liu L; Chen X; Hu C; Zhang D; Shao Z; Jin Q; Yang J; Xie H; Liu B; Hu M; Ke K
Sci Rep; 2018 May; 8(1):8440. PubMed ID: 29855504
[TBL] [Abstract][Full Text] [Related]
10. In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer.
Abu-Jamous B; Buffa FM; Harris AL; Nandi AK
Mol Cancer; 2017 Jun; 16(1):105. PubMed ID: 28619028
[TBL] [Abstract][Full Text] [Related]
11. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
Ye H; Zhang X; Chen Y; Liu Q; Wei J
Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
[TBL] [Abstract][Full Text] [Related]
12. Tumour suppressor death-associated protein kinase targets cytoplasmic HIF-1α for Th17 suppression.
Chou TF; Chuang YT; Hsieh WC; Chang PY; Liu HY; Mo ST; Hsu TS; Miaw SC; Chen RH; Kimchi A; Lai MZ
Nat Commun; 2016 Jun; 7():11904. PubMed ID: 27312851
[TBL] [Abstract][Full Text] [Related]
13. Novel and emerging targeted-based cancer therapy agents and methods.
Hojjat-Farsangi M
Tumour Biol; 2015 Feb; 36(2):543-56. PubMed ID: 25663495
[TBL] [Abstract][Full Text] [Related]
14. Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction.
Cardoso R; Love R; Nilsson CL; Bergqvist S; Nowlin D; Yan J; Liu KK; Zhu J; Chen P; Deng YL; Dyson HJ; Greig MJ; Brooun A
Protein Sci; 2012 Dec; 21(12):1885-96. PubMed ID: 23033253
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.
Jones DT; Harris AL
Expert Opin Ther Targets; 2012 May; 16(5):463-80. PubMed ID: 22512262
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
17. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.
Albadari N; Deng S; Li W
Expert Opin Drug Discov; 2019 Jul; 14(7):667-682. PubMed ID: 31070059
[No Abstract] [Full Text] [Related]
18. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.
Mimeault M; Batra SK
J Cell Mol Med; 2013 Jan; 17(1):30-54. PubMed ID: 23301832
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
